Plethico Pharmaceuticals
Plethico Pharmaceuticals
HealthcareTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has reduced debt.
- Stock is trading at 0.02 times its book value
Weaknesses
6- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 9.07% over last 3 years.
- Contingent liabilities of Rs.1,518 Cr.
- Company has high debtors of 198 days.
- Company's cost of borrowing seems high
Growth Rate
Quarterly Results
| Particulars | Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 490 | 480 | 447 | 364 | 310 | 278 | 263 | 111 | 113 |
| Expenses | 459 | 403 | 392 | 265 | 262 | 227 | 211 | 93 | 120 |
| Operating Profit | 32 | 77 | 54 | 100 | 48 | 51 | 52 | 18 | -7 |
| OPM % | 7% | 16% | 12% | 27% | 16% | 18% | 20% | 16% | -6% |
| Other Income | 3 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | -320 |
| Interest | 15 | 35 | 23 | 29 | 57 | 36 | 52 | 12 | 22 |
| Depreciation | 4 | 10 | 7 | 27 | 16 | 15 | 15 | 11 | 16 |
| PBT | 16 | 38 | 24 | 43 | -24 | -1 | -15 | -4 | -365 |
| Tax % | 16% | -18% | 14% | -2% | -51% | 34% | -59% | 0% | -27% |
| Net Profit | 13 | 44 | 21 | 44 | -12 | -2 | -6 | -4 | -266 |
| EPS in Rs | 3.88 | 13.03 | 6.16 | 12.94 | -3.52 | -0.49 | -1.85 | -1.19 | -77.99 |
Profit & Loss
| Particulars | Sep 2006 | Dec 2007 15m | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Mar 2014 15m | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 366 | 549 | 905 | 1,249 | 1,529 | 1,557 | 1,632 | 2,060 | 765 |
| Expenses | 272 | 410 | 774 | 1,014 | 1,191 | 1,342 | 1,470 | 1,766 | 652 |
| Operating Profit | 93 | 140 | 131 | 235 | 338 | 215 | 161 | 294 | 113 |
| OPM % | 26% | 25% | 15% | 19% | 22% | 14% | 10% | 14% | 15% |
| Other Income | 10 | 38 | 16 | 27 | -2 | 23 | 33 | 42 | -320 |
| Interest | 6 | 10 | 23 | 35 | 40 | 89 | 67 | 175 | 122 |
| Depreciation | 5 | 7 | 16 | 17 | 26 | 18 | 18 | 64 | 58 |
| PBT | 92 | 161 | 109 | 210 | 269 | 131 | 109 | 97 | -386 |
| Tax % | 4% | 2% | -13% | -3% | 9% | 22% | 7% | -14% | — |
| Net Profit | 89 | 158 | 123 | 217 | 244 | 103 | 101 | 111 | -278 |
| EPS in Rs | 25.81 | 46.48 | 36.21 | 63.68 | 71.74 | 30.21 | 29.79 | 32.49 | -81.52 |
| Div. Payout % | 10% | 5% | 7% | 4% | 3% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Sep 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Mar 2014 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 34 | 34 | 34 | 34 | 34 | 34 | 34 | 34 |
| Reserves | 412 | 559 | 702 | 856 | 1,037 | 1,331 | 1,333 | 1,580 |
| Borrowings | 95 | 383 | 682 | 612 | 581 | 1,069 | 1,187 | 1,391 |
| Other Liabilities | 48 | 43 | 92 | 87 | 180 | 126 | 177 | 309 |
| Total Liabilities | 588 | 1,018 | 1,509 | 1,590 | 1,832 | 2,559 | 2,732 | 3,315 |
| Fixed Assets | 177 | 111 | 425 | 401 | 411 | 445 | 427 | 986 |
| CWIP | 24 | 2 | 191 | 213 | 255 | 401 | 395 | 0 |
| Investments | 43 | 409 | 199 | 199 | 199 | 199 | 199 | 199 |
| Other Assets | 344 | 496 | 694 | 776 | 967 | 1,514 | 1,711 | 2,130 |
| Total Assets | 588 | 1,018 | 1,509 | 1,590 | 1,832 | 2,559 | 2,732 | 3,315 |
Cash Flow
| Particulars | Sep 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Mar 2014 |
|---|---|---|---|---|---|---|---|---|
| Operating | -39 | 70 | 138 | 165 | 176 | -272 | -61 | 244 |
| Investing | -39 | -255 | -409 | -14 | -101 | -15 | 23 | -490 |
| Financing | 146 | 266 | 167 | -147 | -85 | 357 | -40 | 249 |
| Net Cash Flow | 68 | 81 | -105 | 4 | -10 | 70 | -79 | 2 |
| Free Cash Flow | -65 | 67 | -248 | 152 | 91 | -373 | -56 | -386 |
| CFO/OP | -36 | 50 | 115 | 64 | 55 | -118 | -43 | 78 |
Ratios
| Particulars | Sep 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Mar 2014 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 232 | 177 | 157 | 133 | 152 | 228 | 274 | 198 |
| Inventory Days | 42 | 17 | 114 | 84 | 73 | 76 | 72 | 60 |
| Days Payable | 25 | 16 | 66 | 35 | 62 | 23 | 24 | 32 |
| Cash Conversion Cycle | 249 | 177 | 205 | 181 | 163 | 281 | 322 | 225 |
| Working Capital Days | 234 | 204 | 212 | 177 | 171 | 300 | 337 | 281 |
| ROCE % | — | 20% | 17% | 17% | 20% | 14% | 7% | 10% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Plethico Pharmaceuticals insights
53 extracted metrics + investor summaries across FY07–FY14.
Documents
Frequently Asked Questions about Plethico Pharmaceuticals
What does Plethico Pharmaceuticals Ltd do?
Which sector does Plethico Pharmaceuticals Ltd belong to?
Company Information
Plethico Pharmaceuticals Ltd is an India-based healthcare pharmaceutical company engaged in the manufacture and marketing of pharmaceutical and allied healthcare.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/PLETHICO.md for Plethico Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.